75A50122C00079

THE OBJECTIVE OF THIS CONTRACT IS TO DEVELOP A SECOND-GENERATION ASSAY FOR THE ORAQUICK EBOLA RAPID ANTIGEN TEST AS A SUSTAINABLE, ENHANCED TEST INCLUDING ALTERNATIVE REAGENTS (ANTIBODY AND ANTIGEN) WITH CONTINUED AVAILABILITY, EXTENDED SHELF-LIFE, A

Research the contractor View USAspending source Save to my pursuit research

Award details

Obligations, current value and potential value describe different measures; they are never added together.

Field	Reported value
Agency	Department of Health and Human Services
Office	BARDA - ASPR / DAAPPO / BARDA DCMA
NAICS	541714 — Research and Development in Biotechnology (except Nanobiotechnology)
PSC	AN13 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT
Parent award / vehicle	Not reported
Set-aside	NO SET ASIDE USED.
Pricing type	COST PLUS FIXED FEE
Obligations	$15.5M
Current contract value	$15.5M
Potential contract value / ceiling	$15.5M
Start date	Jan 3, 2023
Current end date	Jun 30, 2027
Potential end date	Jun 30, 2027
Latest award activity	Sep 4, 2025
Source loaded	Sep 26, 2026

Funding and modification history

Showing the latest 9 of 9 loaded transactions. Negative values are deobligations.

Date	Modification	Obligation change	Description
Sep 4, 2025	P00008	$0	THE OBJECTIVE OF THIS CONTRACT IS TO DEVELOP A SECOND-GENERATION ASSAY FOR THE ORAQUICK EBOLA RAPID ANTIGEN TEST AS A SUSTAINABLE, ENHANCED TEST INCLUDING ALTERNATIVE REAGENTS (ANTIBODY AND ANTIGEN) WITH CONTINUED AVAILABILITY, EXTENDED SHELF-LIFE, A
Mar 13, 2025	P00007	$0	THE OBJECTIVE OF THIS CONTRACT IS TO DEVELOP A SECOND-GENERATION ASSAY FOR THE ORAQUICK EBOLA RAPID ANTIGEN TEST AS A SUSTAINABLE, ENHANCED TEST INCLUDING ALTERNATIVE REAGENTS (ANTIBODY AND ANTIGEN) WITH CONTINUED AVAILABILITY, EXTENDED SHELF-LIFE, A
Dec 4, 2024	P00006	$0	THE OBJECTIVE OF THIS CONTRACT IS TO DEVELOP A SECOND-GENERATION ASSAY FOR THE ORAQUICK EBOLA RAPID ANTIGEN TEST AS A SUSTAINABLE, ENHANCED TEST INCLUDING ALTERNATIVE REAGENTS (ANTIBODY AND ANTIGEN) WITH CONTINUED AVAILABILITY, EXTENDED SHELF-LIFE, A
Jun 13, 2024	P00005	$0	THE OBJECTIVE OF THIS CONTRACT IS TO DEVELOP A SECOND-GENERATION ASSAY FOR THE ORAQUICK EBOLA RAPID ANTIGEN TEST AS A SUSTAINABLE, ENHANCED TEST INCLUDING ALTERNATIVE REAGENTS (ANTIBODY AND ANTIGEN) WITH CONTINUED AVAILABILITY, EXTENDED SHELF-LIFE, A
Apr 24, 2024	P00004	$0	THE OBJECTIVE OF THIS CONTRACT IS TO DEVELOP A SECOND-GENERATION ASSAY FOR THE ORAQUICK EBOLA RAPID ANTIGEN TEST AS A SUSTAINABLE, ENHANCED TEST INCLUDING ALTERNATIVE REAGENTS (ANTIBODY AND ANTIGEN) WITH CONTINUED AVAILABILITY, EXTENDED SHELF-LIFE, A
Sep 19, 2023	P00003	$6.9M	THE OBJECTIVE OF THIS CONTRACT IS TO DEVELOP A SECOND-GENERATION ASSAY FOR THE ORAQUICK EBOLA RAPID ANTIGEN TEST AS A SUSTAINABLE, ENHANCED TEST INCLUDING ALTERNATIVE REAGENTS (ANTIBODY AND ANTIGEN) WITH CONTINUED AVAILABILITY, EXTENDED SHELF-LIFE, A
Dec 8, 2022	P00002	$0	THE OBJECTIVE OF THIS CONTRACT IS TO DEVELOP A SECOND-GENERATION ASSAY FOR THE ORAQUICK EBOLA RAPID ANTIGEN TEST AS A SUSTAINABLE, ENHANCED TEST INCLUDING ALTERNATIVE REAGENTS (ANTIBODY AND ANTIGEN) WITH CONTINUED AVAILABILITY, EXTENDED SHELF-LIFE, A
Oct 5, 2022	P00001	$0	THE OBJECTIVE OF THIS CONTRACT IS TO DEVELOP A SECOND-GENERATION ASSAY FOR THE ORAQUICK EBOLA RAPID ANTIGEN TEST AS A SUSTAINABLE, ENHANCED TEST INCLUDING ALTERNATIVE REAGENTS (ANTIBODY AND ANTIGEN) WITH CONTINUED AVAILABILITY, EXTENDED SHELF-LIFE, A
Sep 27, 2022	0	$8.6M	THE OBJECTIVE OF THIS CONTRACT IS TO DEVELOP A SECOND-GENERATION ASSAY FOR THE ORAQUICK EBOLA RAPID ANTIGEN TEST AS A SUSTAINABLE, ENHANCED TEST INCLUDING ALTERNATIVE REAGENTS (ANTIBODY AND ANTIGEN) WITH CONTINUED AVAILABILITY, EXTENDED SHELF-LIFE, A

Estimated positioning window

Nov 1, 2026 – Jan 30, 2027

Recompete signal:

75/100

Why this recompete signal

Contract timing and recorded acquisition signals at the time of calculation.

Stored score: 75/100. Available recorded signals: 70 points.

Contract end 2027-06-30 (241 days from calculation): +35 points
121 historical awards in this buyer and category group: +15 points
9 recorded award transactions: +10 points
Latest award action: 2025-09-04: +0 points
Parent award identifier recorded: +0 points
Solicitation identifier recorded: +10 points
Linked official forecast: +0 points
Calculated on: 2026-11-01 10:17:53.997580+00:00

The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.

Rule-based research score; it does not measure your chance of winning.

This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.

USAspending award record

. Rule-based research score; positioning dates are estimates.

Recompete score calculated Nov 1, 2026.

Research next steps

Check the linked forecast or SAM for a confirmed solicitation and current timing.
Check the stated set-aside against the solicitation and current certifications.
Review the award scope and buyer evidence before making a bid/no-bid decision.